tirzepatide
updated
Tirzepatide is a once-weekly injection that reduces appetite and lowers blood sugar. It is sold as Zepbound for weight management and obesity-related sleep apnea, and as Mounjaro for type 2 diabetes.
Dual GIP and GLP-1 receptor agonist
- Prescription medicine
- Once-weekly injection
- Activates GIP and GLP-1 receptors
What is tirzepatide approved to treat?
In the US, Zepbound is approved for long-term weight management in adults with obesity, or overweight with a weight-related condition. It also treats moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro treats type 2 diabetes in adults and children age 10 years and older.
| Product | Approved use | Alongside treatment |
|---|---|---|
| Zepbound | Long-term weight management; moderate-to-severe obstructive sleep apnea in adults with obesity | Reduced-calorie diet and increased physical activity |
| Mounjaro | Blood-sugar control in type 2 diabetes, age 10 years and older | Diet and exercise |
Zepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceMounjaro label · type 2 diabetes
FDA prescribing information
Eli Lilly and Company. Mounjaro prescribing information, revised January 2026.
Mounjaro is approved for blood-sugar control in adults and children age 10 years and older with type 2 diabetes.
- Participants / model
- Adults and pediatric patients age 10 years and older with type 2 diabetes
- Treatment
- Prescription tirzepatide injection sold as Mounjaro
- Study design
- Regulatory prescribing information
This indication is distinct from Zepbound's weight-management and OSA indications.
Read the original sourceHow much weight loss did the main obesity trial show?
SURMOUNT-1 randomized 2,539 adults with obesity, or overweight plus a complication, who did not have diabetes. At 72 weeks, mean weight change was -15.0%, -19.5%, and -20.9% across the three tirzepatide groups, compared with -3.1% with placebo.
- Tirzepatide 5 mg
- -15%
- Tirzepatide 10 mg
- -19.5%
- Tirzepatide 15 mg
- -20.9%
- Placebo
- -3.1%
Participants also received lifestyle support. Gastrointestinal side effects were the most common adverse effects and occurred mainly while doses were being increased.
SURMOUNT-1 · 72-week obesity trial
Randomized, double-blind trial
Jastreboff AM et al. New England Journal of Medicine, 2022.
Among 2,539 adults without diabetes, mean weight change at 72 weeks was -15.0%, -19.5%, and -20.9% across tirzepatide groups versus -3.1% with placebo.
- Participants / model
- Adults with obesity, or overweight plus a weight-related complication, without diabetes
- Treatment
- Once-weekly tirzepatide at three trial doses or placebo, with lifestyle intervention
- Follow-up
- 72 weeks
- Study design
- Phase 3 randomized, double-blind, placebo-controlled trial
- Funding
- Eli Lilly
People with diabetes were excluded. All groups received lifestyle support.
Read the original sourceHas tirzepatide been compared directly with semaglutide for obesity?
SURMOUNT-5 randomized 751 adults with obesity and no type 2 diabetes to maximum-tolerated tirzepatide or semaglutide for 72 weeks. Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. The comparison was open label and funded by tirzepatide's manufacturer.
- Tirzepatide
- -20.2%
- Semaglutide
- -13.7%
The study doses were tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg once weekly, depending on tolerability. Gastrointestinal side effects were most common in both groups, mainly while doses were being increased.
SURMOUNT-5 · direct obesity comparison
Randomized, open-label active-comparator trial
Aronne LJ et al. New England Journal of Medicine, 2025.
Among 751 adults with obesity and no type 2 diabetes, mean weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide; waist circumference fell 18.4 cm and 13.0 cm, respectively.
- Participants / model
- Adults with obesity without type 2 diabetes
- Treatment
- Maximum-tolerated tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg once weekly
- Follow-up
- 72 weeks
- Study design
- Phase 3b randomized, open-label, controlled trial
- Funding
- Eli Lilly
Participants and investigators knew which drug was assigned. Both drugs were increased to the maximum tolerated study dose.
Read the original sourceHow much of the lost weight was lean mass?
A DXA substudy measured 160 SURMOUNT-1 participants at baseline and week 72. With tirzepatide, fat mass fell 33.9% and lean mass fell 10.9%. About 75% of lost weight was fat mass and 25% was lean mass in an analysis performed after the trial. The fat-to-lean proportion was similar with placebo.
DXA lean mass includes water, organs, connective tissue and muscle. The 25% figure therefore does not mean that a quarter of the lost weight was skeletal muscle. DXA does not measure strength.
DXA substudy · fat and lean mass
Prespecified substudy with post hoc analyses
Look M et al. Diabetes, Obesity and Metabolism, 2025.
Among 160 participants with baseline and week-72 DXA, tirzepatide changed fat mass by -33.9% and lean mass by -10.9%; roughly 75% of lost weight was fat and 25% lean mass.
- Participants / model
- 160 of 2,539 SURMOUNT-1 participants with paired DXA measurements
- Treatment
- Pooled tirzepatide groups or placebo
- Follow-up
- 72 weeks
- Study design
- DXA substudy; weight-loss composition partition was post hoc
- Funding
- Eli Lilly
Lean mass is not identical to skeletal muscle or strength, and the substudy was small relative to the parent trial.
Read the original sourceDoes the weight stay off after tirzepatide is stopped?
Participants who stopped tirzepatide in SURMOUNT-4 regained weight on average. Everyone first received tirzepatide for 36 weeks; 670 participants who completed this period and tolerated the study dose were then randomized to continue it or switch to placebo for another 52 weeks. From randomization, weight changed -5.5% with continued treatment and +14.0% after the switch to placebo.
These percentage changes start from week 36, after the initial weight loss. The comparison only included people who completed the first 36 weeks of treatment.
SURMOUNT-4 · continuation versus withdrawal
Randomized withdrawal trial
Aronne LJ et al. JAMA, 2024.
After a 36-week tirzepatide lead-in, continued treatment produced a further 5.5% mean loss from week 36 to 88, while participants switched to placebo regained 14.0% on average.
- Participants / model
- 670 adults without diabetes who completed the tirzepatide lead-in and reached a tolerated trial dose
- Treatment
- Continue tirzepatide or switch to placebo after 36 weeks of open-label tirzepatide
- Follow-up
- 36-week lead-in plus 52-week randomized period
- Study design
- Phase 3 randomized, double-blind withdrawal trial
- Funding
- Eli Lilly
Only participants who completed the initial 36 weeks and tolerated the study dose entered the randomized comparison.
Read the original sourceDoes tirzepatide improve sleep apnea?
SURMOUNT-OSA ran two 52-week randomized trials in 469 adults with obesity and moderate-to-severe obstructive sleep apnea, separating people not using positive airway pressure from people using it. The placebo-corrected apnea-hypopnea-index changes were -20.0 and -23.8 events per hour in the two trials.
The trials also found improvements in body weight, hypoxic burden, inflammatory marker, systolic blood pressure, and sleep-related patient reports. They do not support stopping positive airway pressure without a reassessment of the person's sleep apnea.
SURMOUNT-OSA · apnea-hypopnea outcomes
Two randomized, double-blind trials
Malhotra A et al. New England Journal of Medicine, 2024.
In separate trials without and with baseline positive-airway-pressure use, placebo-corrected AHI changes at 52 weeks were -20.0 and -23.8 events per hour.
- Participants / model
- 469 adults with obesity and moderate-to-severe obstructive sleep apnea
- Treatment
- Maximum-tolerated tirzepatide 10 or 15 mg or placebo plus lifestyle intervention
- Follow-up
- 52 weeks
- Study design
- Two randomized, double-blind, placebo-controlled phase 3 trials separated by PAP use
- Funding
- Eli Lilly
The trial does not support unsupervised withdrawal of positive airway pressure therapy.
Read the original sourceZepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceDid tirzepatide improve outcomes in obesity-related HFpEF?
SUMMIT randomized 731 people with obesity and heart failure with preserved ejection fraction. Cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo over a median 104 weeks, but the difference was driven by fewer worsening-heart-failure events, not fewer cardiovascular deaths.
Health status also improved: the between-group difference in the Kansas City Cardiomyopathy Questionnaire clinical summary score was 6.9 points at 52 weeks. Gastrointestinal adverse events caused more treatment discontinuations with tirzepatide.
SUMMIT · HFpEF with obesity
Randomized, double-blind outcomes trial
Packer M et al. New England Journal of Medicine, 2025.
Among 731 people with HFpEF and obesity, cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo; the KCCQ-CSS between-group difference was 6.9 points at 52 weeks.
- Participants / model
- Adults with symptomatic HFpEF, ejection fraction at least 50%, and BMI at least 30
- Treatment
- Tirzepatide titrated up to 15 mg weekly or placebo added to background therapy
- Follow-up
- At least 52 weeks; median follow-up 104 weeks
- Study design
- International randomized, double-blind, placebo-controlled trial
- Funding
- Eli Lilly
The composite benefit was driven by worsening-heart-failure events; cardiovascular death alone was not lower.
Read the original sourceDoes the liver-biopsy trial make MASH an approved use?
In SYNERGY-NASH, resolution of MASH without worsening fibrosis occurred in 44%, 56%, and 62% across tirzepatide groups versus 10% with placebo. The 52-week phase 2 trial enrolled 190 people with biopsy-confirmed MASH and F2 or F3 fibrosis; 157 had evaluable week-52 biopsies, and missing values were imputed. The trial did not make MASH an approved use.
The separate fibrosis-improvement endpoint ranged from 51% to 55% with tirzepatide versus 30% with placebo. MASH is not an approved indication for Zepbound or Mounjaro in the February and January 2026 US labels.
SYNERGY-NASH · phase 2 liver-biopsy trial
Randomized, double-blind phase 2 trial
Loomba R et al. New England Journal of Medicine, 2024.
MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% across tirzepatide groups versus 10% with placebo at 52 weeks; 157 of 190 randomized participants had evaluable week-52 biopsies.
- Participants / model
- Adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis
- Treatment
- Three tirzepatide groups or placebo
- Follow-up
- 52 weeks
- Study design
- Multicenter randomized, double-blind, placebo-controlled dose-finding phase 2 trial
- Funding
- Eli Lilly
Week-52 biopsies were missing for 33 participants. Missing outcomes were estimated using the placebo group's pattern.
Read the original sourceZepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceMounjaro label · type 2 diabetes
FDA prescribing information
Eli Lilly and Company. Mounjaro prescribing information, revised January 2026.
Mounjaro is approved for blood-sugar control in adults and children age 10 years and older with type 2 diabetes.
- Participants / model
- Adults and pediatric patients age 10 years and older with type 2 diabetes
- Treatment
- Prescription tirzepatide injection sold as Mounjaro
- Study design
- Regulatory prescribing information
This indication is distinct from Zepbound's weight-management and OSA indications.
Read the original sourceDid tirzepatide reduce major cardiovascular events?
SURPASS-CVOT randomized 13,165 people with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide. The three-point major cardiovascular-event outcome occurred in 12.2% versus 13.1% over a median four years. Tirzepatide was noninferior to dulaglutide, but superiority on the primary endpoint was not established.
The hazard ratio was 0.92 with a 95.3% confidence interval from 0.83 to 1.01. This was an active-comparator trial against a drug with prior cardiovascular benefit, not a placebo trial.
SURPASS-CVOT · active-comparator cardiovascular trial
Randomized, double-blind noninferiority trial
Nicholls SJ et al. New England Journal of Medicine, 2025.
Among 13,165 people with type 2 diabetes and atherosclerotic cardiovascular disease, three-point MACE occurred in 12.2% with tirzepatide and 13.1% with dulaglutide; tirzepatide was noninferior but not superior on the primary endpoint.
- Participants / model
- Adults with type 2 diabetes and established atherosclerotic cardiovascular disease
- Treatment
- Weekly tirzepatide up to 15 mg or dulaglutide 1.5 mg
- Follow-up
- Median follow-up about four years
- Study design
- Active-comparator, double-blind, randomized noninferiority trial
- Funding
- Eli Lilly
Dulaglutide is an active comparator with prior cardiovascular-outcome benefit; this was not a placebo comparison.
Read the original sourceWhat side effects can tirzepatide cause?
Nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion are common. The Zepbound label also warns about severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis, serious hypersensitivity, hypoglycemia when combined with insulin or a secretagogue, diabetic-retinopathy complications, and aspiration during anesthesia or deep sedation.
Zepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceWhich medicines or situations change the risk?
Tirzepatide delays gastric emptying and can affect absorption of oral medicines. Oral hormonal contraceptives may be less effective after starting treatment or increasing the dose. Insulin and insulin secretagogues can raise hypoglycemia risk, and pregnancy is a reason to discontinue weight-loss treatment.
- Review oral medicines with a narrow therapeutic window or absorption-sensitive timing.
- Switch to a non-oral contraceptive or add a barrier method for four weeks after starting and for four weeks after each dose increase.
- Tell the procedural team about use before anesthesia or deep sedation because delayed gastric emptying can leave stomach contents behind.
Zepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceHow does tirzepatide work?
Tirzepatide activates GIP and GLP-1 receptors. It reduces appetite and food intake, increases insulin release when blood sugar is high, and delays stomach emptying. Delayed stomach emptying can also affect how oral medicines are absorbed.
Zepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceMounjaro label · type 2 diabetes
FDA prescribing information
Eli Lilly and Company. Mounjaro prescribing information, revised January 2026.
Mounjaro is approved for blood-sugar control in adults and children age 10 years and older with type 2 diabetes.
- Participants / model
- Adults and pediatric patients age 10 years and older with type 2 diabetes
- Treatment
- Prescription tirzepatide injection sold as Mounjaro
- Study design
- Regulatory prescribing information
This indication is distinct from Zepbound's weight-management and OSA indications.
Read the original sourceStudies and sources
Zepbound label · obesity and OSA
FDA prescribing information
Eli Lilly and Company. Zepbound prescribing information, revised February 2026.
Defines the current Zepbound indications, product presentations, contraindications, common adverse reactions, serious warnings, oral-drug and contraceptive cautions, and pregnancy guidance.
- Participants / model
- Adults meeting the labeled chronic weight-management criteria; adults with obesity and moderate-to-severe OSA
- Treatment
- Prescription tirzepatide injection sold as Zepbound
- Study design
- Regulatory prescribing information
Zepbound is not recommended with another tirzepatide product or a GLP-1 receptor agonist.
Read the original sourceMounjaro label · type 2 diabetes
FDA prescribing information
Eli Lilly and Company. Mounjaro prescribing information, revised January 2026.
Mounjaro is approved for blood-sugar control in adults and children age 10 years and older with type 2 diabetes.
- Participants / model
- Adults and pediatric patients age 10 years and older with type 2 diabetes
- Treatment
- Prescription tirzepatide injection sold as Mounjaro
- Study design
- Regulatory prescribing information
This indication is distinct from Zepbound's weight-management and OSA indications.
Read the original sourceSURMOUNT-1 · 72-week obesity trial
Randomized, double-blind trial
Jastreboff AM et al. New England Journal of Medicine, 2022.
Among 2,539 adults without diabetes, mean weight change at 72 weeks was -15.0%, -19.5%, and -20.9% across tirzepatide groups versus -3.1% with placebo.
- Participants / model
- Adults with obesity, or overweight plus a weight-related complication, without diabetes
- Treatment
- Once-weekly tirzepatide at three trial doses or placebo, with lifestyle intervention
- Follow-up
- 72 weeks
- Study design
- Phase 3 randomized, double-blind, placebo-controlled trial
- Funding
- Eli Lilly
People with diabetes were excluded. All groups received lifestyle support.
Read the original sourceSURMOUNT-4 · continuation versus withdrawal
Randomized withdrawal trial
Aronne LJ et al. JAMA, 2024.
After a 36-week tirzepatide lead-in, continued treatment produced a further 5.5% mean loss from week 36 to 88, while participants switched to placebo regained 14.0% on average.
- Participants / model
- 670 adults without diabetes who completed the tirzepatide lead-in and reached a tolerated trial dose
- Treatment
- Continue tirzepatide or switch to placebo after 36 weeks of open-label tirzepatide
- Follow-up
- 36-week lead-in plus 52-week randomized period
- Study design
- Phase 3 randomized, double-blind withdrawal trial
- Funding
- Eli Lilly
Only participants who completed the initial 36 weeks and tolerated the study dose entered the randomized comparison.
Read the original sourceSURMOUNT-5 · direct obesity comparison
Randomized, open-label active-comparator trial
Aronne LJ et al. New England Journal of Medicine, 2025.
Among 751 adults with obesity and no type 2 diabetes, mean weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide; waist circumference fell 18.4 cm and 13.0 cm, respectively.
- Participants / model
- Adults with obesity without type 2 diabetes
- Treatment
- Maximum-tolerated tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg once weekly
- Follow-up
- 72 weeks
- Study design
- Phase 3b randomized, open-label, controlled trial
- Funding
- Eli Lilly
Participants and investigators knew which drug was assigned. Both drugs were increased to the maximum tolerated study dose.
Read the original sourceDXA substudy · fat and lean mass
Prespecified substudy with post hoc analyses
Look M et al. Diabetes, Obesity and Metabolism, 2025.
Among 160 participants with baseline and week-72 DXA, tirzepatide changed fat mass by -33.9% and lean mass by -10.9%; roughly 75% of lost weight was fat and 25% lean mass.
- Participants / model
- 160 of 2,539 SURMOUNT-1 participants with paired DXA measurements
- Treatment
- Pooled tirzepatide groups or placebo
- Follow-up
- 72 weeks
- Study design
- DXA substudy; weight-loss composition partition was post hoc
- Funding
- Eli Lilly
Lean mass is not identical to skeletal muscle or strength, and the substudy was small relative to the parent trial.
Read the original sourceSURMOUNT-OSA · apnea-hypopnea outcomes
Two randomized, double-blind trials
Malhotra A et al. New England Journal of Medicine, 2024.
In separate trials without and with baseline positive-airway-pressure use, placebo-corrected AHI changes at 52 weeks were -20.0 and -23.8 events per hour.
- Participants / model
- 469 adults with obesity and moderate-to-severe obstructive sleep apnea
- Treatment
- Maximum-tolerated tirzepatide 10 or 15 mg or placebo plus lifestyle intervention
- Follow-up
- 52 weeks
- Study design
- Two randomized, double-blind, placebo-controlled phase 3 trials separated by PAP use
- Funding
- Eli Lilly
The trial does not support unsupervised withdrawal of positive airway pressure therapy.
Read the original sourceSUMMIT · HFpEF with obesity
Randomized, double-blind outcomes trial
Packer M et al. New England Journal of Medicine, 2025.
Among 731 people with HFpEF and obesity, cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo; the KCCQ-CSS between-group difference was 6.9 points at 52 weeks.
- Participants / model
- Adults with symptomatic HFpEF, ejection fraction at least 50%, and BMI at least 30
- Treatment
- Tirzepatide titrated up to 15 mg weekly or placebo added to background therapy
- Follow-up
- At least 52 weeks; median follow-up 104 weeks
- Study design
- International randomized, double-blind, placebo-controlled trial
- Funding
- Eli Lilly
The composite benefit was driven by worsening-heart-failure events; cardiovascular death alone was not lower.
Read the original sourceSYNERGY-NASH · phase 2 liver-biopsy trial
Randomized, double-blind phase 2 trial
Loomba R et al. New England Journal of Medicine, 2024.
MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% across tirzepatide groups versus 10% with placebo at 52 weeks; 157 of 190 randomized participants had evaluable week-52 biopsies.
- Participants / model
- Adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis
- Treatment
- Three tirzepatide groups or placebo
- Follow-up
- 52 weeks
- Study design
- Multicenter randomized, double-blind, placebo-controlled dose-finding phase 2 trial
- Funding
- Eli Lilly
Week-52 biopsies were missing for 33 participants. Missing outcomes were estimated using the placebo group's pattern.
Read the original sourceSURPASS-CVOT · active-comparator cardiovascular trial
Randomized, double-blind noninferiority trial
Nicholls SJ et al. New England Journal of Medicine, 2025.
Among 13,165 people with type 2 diabetes and atherosclerotic cardiovascular disease, three-point MACE occurred in 12.2% with tirzepatide and 13.1% with dulaglutide; tirzepatide was noninferior but not superior on the primary endpoint.
- Participants / model
- Adults with type 2 diabetes and established atherosclerotic cardiovascular disease
- Treatment
- Weekly tirzepatide up to 15 mg or dulaglutide 1.5 mg
- Follow-up
- Median follow-up about four years
- Study design
- Active-comparator, double-blind, randomized noninferiority trial
- Funding
- Eli Lilly
Dulaglutide is an active comparator with prior cardiovascular-outcome benefit; this was not a placebo comparison.
Read the original sourceWhy is tirzepatide in S tier?
Tirzepatide is in S tier because large randomized trials have shown weight loss, improved blood-sugar control and reduced sleep-apnea severity. Zepbound and Mounjaro have US approvals for these uses.
read Tirzepatide in the reptides guide, chapter 02: 13 pages, free to read.